Company Overview

Cognetivity Neurosciences Ltd. (OTCQB: CGNSF) is a Canadian technology and medical diagnostics company focused on developing cognitive assessment tools that use artificial intelligence and machine learning to assist in the early detection of cognitive impairment and neurological conditions. The company operates at the intersection of digital health, neuroscience, and medical technology, with a primary emphasis on computerized cognitive testing platforms intended for use in healthcare and clinical environments. Its principal product platform is the Integrated Cognitive Assessment (ICA), a rapid computerized assessment designed to evaluate cognitive performance without relying heavily on language, education level, or cultural background.

The company’s core revenue strategy has centered on commercialization of its cognitive assessment technology through healthcare providers, research institutions, and potential licensing arrangements. Cognetivity has positioned itself as a developer of scalable, non-invasive digital diagnostics that may support earlier identification of conditions such as dementia, mild cognitive impairment, and other neurological disorders. The company was founded in 2017 and has evolved from a neuroscience-focused technology startup into a publicly traded medical technology company pursuing regulatory approvals, commercial partnerships, and broader international adoption of its cognitive testing platform.

Business Operations

Cognetivity’s operations are primarily organized around the development, validation, and commercialization of its Integrated Cognitive Assessment (ICA) platform and related digital health technologies. The company generates potential revenue through software licensing, clinical deployment agreements, partnerships with healthcare providers, and collaborations involving cognitive assessment applications. Public disclosures indicate that the ICA platform has been evaluated in clinical and research settings and incorporates artificial intelligence models designed to detect subtle changes in cognitive processing speed and accuracy.

The company maintains operations and commercial activities in both Canada and the United Kingdom, with additional efforts directed toward broader international healthcare markets. Cognetivity’s technology assets include proprietary cognitive testing algorithms, data analytics capabilities, and digital assessment software intended for deployment across tablets and other digital devices. The company has also pursued collaborations with healthcare institutions and academic organizations to support validation studies and commercialization efforts. Data regarding the scale of long-term commercial partnerships and recurring revenue remains limited based on available public filings.

Strategic Position & Investments

Cognetivity’s strategic direction has focused on expanding adoption of AI-enabled cognitive diagnostics within healthcare systems and clinical research markets. Growth initiatives have included seeking regulatory clearances, strengthening clinical validation data, and pursuing partnerships that may support deployment of the ICA platform across hospitals, memory clinics, and neurological care providers. The company has also emphasized the potential applicability of its technology in monitoring cognitive health in conditions beyond dementia, including concussion assessment and neurodegenerative disease management.

The company’s investment priorities have largely centered on research and development, software enhancement, and commercialization infrastructure. Public filings and investor materials indicate continued efforts to refine machine learning capabilities associated with the ICA platform and to expand the underlying cognitive performance database used in analytical modeling. While Cognetivity has discussed international market opportunities and broader healthcare integration strategies, publicly available information regarding major acquisitions, large-scale subsidiaries, or extensive portfolio investments remains limited. Data inconclusive based on available public sources regarding material acquisition activity.

Geographic Footprint

Cognetivity Neurosciences Ltd. is headquartered in Canada, while maintaining significant operational and development activities in the United Kingdom. The company’s cognitive assessment technologies have been promoted in multiple healthcare markets, with strategic attention directed toward Europe, North America, and selected international clinical research environments. Its operational footprint reflects a combination of software development, clinical validation work, and commercialization efforts tied to healthcare providers and research institutions.

The company’s market presence has primarily been associated with digital cognitive testing initiatives rather than large-scale physical infrastructure. Public disclosures indicate efforts to establish international healthcare relationships and regulatory positioning for broader adoption of the ICA platform. While Cognetivity has referenced opportunities in additional global markets, the extent of sustained commercial penetration across continents remains developing based on currently available public information.

Leadership & Governance

Cognetivity’s leadership team has combined backgrounds in neuroscience, artificial intelligence, healthcare technology, and business development. The company’s governance structure follows the framework typical of publicly traded Canadian corporations, with executive oversight directed toward advancing commercialization of digital cognitive diagnostics and expanding clinical adoption of its technologies. Leadership communications have consistently emphasized early detection of neurological conditions, scalable AI-enabled healthcare solutions, and evidence-based validation of cognitive assessment tools.

Key executives and leadership figures have included:

• Dr. Sina Habibi – Chief Executive Officer
• Dr. Aida Moghaddam – Chief Scientific Officer
• Brent Suen – Chief Financial Officer
• Dr. Hossein Rashidi – Founder and technology contributor associated with development initiatives

The company’s stated strategic vision has focused on improving accessibility and efficiency in cognitive assessment through artificial intelligence-driven diagnostics that can be deployed across diverse healthcare environments. Public filings, including SEC filings and Canadian securities disclosures, indicate ongoing emphasis on clinical validation, regulatory engagement, and commercial scalability.